Chimeric antigen receptor Treg therapy in transplantation

Siawosh K. Eskandari; Andrea Daccache; Jamil R. Azzi

doi:10.1016/j.it.2023.11.005

Chimeric antigen receptor T_reg therapy in transplantation

Siawosh K. Eskandari^*, Andrea Daccache, Jamil R. Azzi

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

6 Citations (Scopus)

42 Downloads (Pure)

Abstract

In the quest for more precise and effective organ transplantation therapies, chimeric antigen receptor (CAR) regulatory T cell (T_reg) therapies represent a potential cutting-edge advance. This review comprehensively analyses CAR T_regs and how they may address important drawbacks of polyclonal T_regs and conventional immunosuppressants. We examine a growing body of preclinical findings of CAR T_reg therapy in transplantation, discuss CAR T_reg design specifics, and explore established and attractive new targets in transplantation. In addition, we explore present impediments where future studies will be necessary to determine the efficacy of CAR T_regs in reshaping alloimmune responses and transplant microenvironments to reduce reliance on chemical immunosuppressants. Overall, ongoing studies and trials are crucial for understanding the full scope of CAR T_reg therapy in transplantation.

Original language	English
Pages (from-to)	48-61
Number of pages	14
Journal	Trends in Immunology
Volume	45
Issue number	1
DOIs	https://doi.org/10.1016/j.it.2023.11.005
Publication status	Published - Jan-2024

Keywords

antigen-specific immunotherapy
chimeric antigen receptors
regulatory T cells
transplant tolerance

Access to Document

10.1016/j.it.2023.11.005

Chimeric antigen receptor Treg therapy in transplantationFinal publisher's version, 1.21 MBLicence: Taverne

Handle.net

Persistent link

Cite this

@article{7f650be9afe4406fbcc70328664dab94,

title = "Chimeric antigen receptor Treg therapy in transplantation",

abstract = "In the quest for more precise and effective organ transplantation therapies, chimeric antigen receptor (CAR) regulatory T cell (Treg) therapies represent a potential cutting-edge advance. This review comprehensively analyses CAR Tregs and how they may address important drawbacks of polyclonal Tregs and conventional immunosuppressants. We examine a growing body of preclinical findings of CAR Treg therapy in transplantation, discuss CAR Treg design specifics, and explore established and attractive new targets in transplantation. In addition, we explore present impediments where future studies will be necessary to determine the efficacy of CAR Tregs in reshaping alloimmune responses and transplant microenvironments to reduce reliance on chemical immunosuppressants. Overall, ongoing studies and trials are crucial for understanding the full scope of CAR Treg therapy in transplantation.",

keywords = "antigen-specific immunotherapy, chimeric antigen receptors, regulatory T cells, transplant tolerance",

author = "Eskandari, {Siawosh K.} and Andrea Daccache and Azzi, {Jamil R.}",

note = "Publisher Copyright: {\textcopyright} 2023 Elsevier Ltd",

year = "2024",

month = jan,

doi = "10.1016/j.it.2023.11.005",

language = "English",

volume = "45",

pages = "48--61",

journal = "Trends in Immunology",

issn = "1471-4906",

publisher = "ELSEVIER SCI LTD",

number = "1",

}

TY - JOUR

T1 - Chimeric antigen receptor Treg therapy in transplantation

AU - Eskandari, Siawosh K.

AU - Daccache, Andrea

AU - Azzi, Jamil R.

PY - 2024/1

Y1 - 2024/1

N2 - In the quest for more precise and effective organ transplantation therapies, chimeric antigen receptor (CAR) regulatory T cell (Treg) therapies represent a potential cutting-edge advance. This review comprehensively analyses CAR Tregs and how they may address important drawbacks of polyclonal Tregs and conventional immunosuppressants. We examine a growing body of preclinical findings of CAR Treg therapy in transplantation, discuss CAR Treg design specifics, and explore established and attractive new targets in transplantation. In addition, we explore present impediments where future studies will be necessary to determine the efficacy of CAR Tregs in reshaping alloimmune responses and transplant microenvironments to reduce reliance on chemical immunosuppressants. Overall, ongoing studies and trials are crucial for understanding the full scope of CAR Treg therapy in transplantation.

AB - In the quest for more precise and effective organ transplantation therapies, chimeric antigen receptor (CAR) regulatory T cell (Treg) therapies represent a potential cutting-edge advance. This review comprehensively analyses CAR Tregs and how they may address important drawbacks of polyclonal Tregs and conventional immunosuppressants. We examine a growing body of preclinical findings of CAR Treg therapy in transplantation, discuss CAR Treg design specifics, and explore established and attractive new targets in transplantation. In addition, we explore present impediments where future studies will be necessary to determine the efficacy of CAR Tregs in reshaping alloimmune responses and transplant microenvironments to reduce reliance on chemical immunosuppressants. Overall, ongoing studies and trials are crucial for understanding the full scope of CAR Treg therapy in transplantation.

KW - antigen-specific immunotherapy

KW - chimeric antigen receptors

KW - regulatory T cells

KW - transplant tolerance

UR - http://www.scopus.com/inward/record.url?scp=85180334575&partnerID=8YFLogxK

U2 - 10.1016/j.it.2023.11.005

DO - 10.1016/j.it.2023.11.005

M3 - Review article

C2 - 38123369

AN - SCOPUS:85180334575

SN - 1471-4906

VL - 45

SP - 48

EP - 61

JO - Trends in Immunology

JF - Trends in Immunology

IS - 1

ER -